Summit Therapeutics Inc.
ivonescimab
epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous non-small cell lung cancer
Resolved
176days ago
Catalyst readout · Jan 12, 2026
What's at stake
A key catalyst for ivonescimab (epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous non-small cell lung cancer) is expected Jan 12, 2026.
Primary source
· SEC 8-K
verified 16h ago
“On January 12, 2026, the Company issued a press release announcing a clinical trial collaboration with GSK plc (“GSK”) to evaluate ivonescimab in combination with GSK’s risvutatug rezetecan (also known as GSK’227), GSK’s novel investigation”